About biomodal
Discover biology in every mode
The genome is the instruction manual for life – but the epigenome provides the highlights and notes to show which sections of the manual need to be read, emphasised, or skipped in response to changing conditions. So we cannot just focus on the static and binary elements of the genetic code. The dynamic epigenetic interactions that govern life are not defined by simple either/ors, but with variation and gradients. This is where the most interesting and important answers await.
We're working to expand the dimensions of genetic discovery
biomodal is focused on building technologies and analytics as research tools for life scientists & clinical developers. We enable you to capture the 6-base genome and provide insight into the complexity and dynamism of cellular interactions. Our solution works with your existing infrastructure, integrating a pre-sequencing workflow with post-sequencing informatics to generate highly accurate genetic and epigenetic data from a single sample in a single run.
Our mission
Creating technologies that bring the dynamism of our ever-changing biology into focus.
Our vision
A future where the holistic understanding of our epigenome and genome vastly improves health and care.
What we believe
Curiosity got us into this
…and curiosity keeps us here. It cultivates in us a perpetual desire for change and discovery. It motivates and challenges. We’re explorers and builders. Each technology we make is imbued with this spirit.
This moment decides our future
While we know our potential, only by urgent action will we realise it. The time to create a better future is this very moment.
Tenacity prevails
Life finds a way where there is none. Inspired by biology, we emulate its tenacity in striving to meet our mission, holding fast, trying every approach, and never giving up.
We elevate each other
Effective risk-taking happens in a supportive environment. That’s why we take responsibility and don’t take ourselves too seriously. We step up and move on together, because our mission is important.
Customer success is the measure of our innovation
The path to validated science is not an easy one. That’s why we orient each aspect of our work, from design and delivery, to service and support, to our customers’ success.
The road to innovation
We’ve been creating and building ways to investigate epigenetic interactions for a long time.
Work published in Science describes the presence of 5hmC in mammalian tissues along with the identification of TET and BGT enzymes responsible for the modification of 5mC to 5hmC. This work shows the importance of epigenetic regulation and the biological relevance of 5hmC.
Work in the Prof. Sir Shankar Balasubramanian lab presents a chemical method for detecting 5mC and 5hmC at single-base resolution.
Founding of CEGX
Launch of Cambridge EpiGenetix, founded by Shankar Balasubramanian and Bobby Yerramilli‑Rao.
Technology evolution
Advancements in detection of 5mC & 5hmC.
Refocusing
Focus shifts to the development of technology to allow for simultaneous sequencing of genetics and epigenetic information in a single sample, providing powerful biological insight into dynamic cellular interactions.
Funding round
Cambridge Epigenetix receives $98 million in funding to develop the duet multiomics technology.
Our paper Simultaneous sequencing of genetic and epigenetic bases in DNA is published in the Nature Biotechnology journal.
Cambridge Epigenetix rebrands as biomodal.
duet multiomics solution +modC is launched, adding modified cytosine to the traditional sequencing of four canonical bases.
Launch of duet multiomics solution evoC to unlock the power of the 6-base genome. This enables sequencing of four canonical bases plus distinguishing 5mC and 5hmC at single base resolution, on the same DNA molecule from 5ng of DNA.
It all started with an epigenetic discovery
duet: a powerful solution combining genetics and epigenetics
Following the discovery of modified cytosine bases, and later their establishment as uniquely important biological markers that complete the 6-base genome, biomodal looked to develop and evolve simpler and more accurate multiomic analysis tools. In addition to the four canonical bases – A, C, G, T – the duet multiomics solutions can distinguish between 5mC and 5hmC, and so provide a powerful tool to support researchers’ efforts to understand, detect, and treat disease.
